A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with Type 2 diabetes

Hormone and Metabolic Research

Volumn 35, Issue 3, 2003, Pages 189-196

  Massi Benedetti, M ^a   Humburg, E ^b   Dressler, A ^b   Ziemen, M ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Basal insulin; Combination Therapy; Glycaemic Control; Hypoglycaemia; Oral Antidiabetic Agents

Indexed keywords

ACARBOSE; C PEPTIDE; GLUCAGON; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADULT; AGED; ARTICLE; BACKACHE; BODY MASS; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INJECTION SITE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; METABOLIC REGULATION; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL DISORDER; OBESITY; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, ISOPHANE; MALE; MIDDLE AGED;

EID: 0038292180     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-39080     Document Type: Article

References (13)

1. Ferrannini E. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev 1998; 19: 477-490
2. Gerich JE. Addressing the insulin secretion defect: a logical first-line approach. Metabolism 2000; 49: 12-16
3. UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865
4. Riddle M. Timely addition of insulin to oral therapy for Type 2 diabetes. Diabetes Care 2002; 25: 395-396
5. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet 1998; 352: 837-853
6. Genuth S. Insulin use in NIDDM. Diabetes Care 1990; 13: 1240-1264
7. Greco A et al. The beta cell function in NIDDM patients with secondary failure: a three year follow-up of combined oral hypoglycemic and insulin therapy. Hormone and Metabolic Research 1992; 24: 280-283
8. Frier B. Hypoglycaemic valleys: an under-recognised problem in type 2 diabetes. Int J Clin Pract Suppl 2002; 129: 12-19
9. Lepore M et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutanwous infusion of insulin lispro. Diabetes 2000; 49: 2142-2148
10. Rosskamp RH, Park G. Long-acting insulin analogs. Diabetes Care 1999; 22: B109-B113
11. Yki-Jarvinen H, Dressier A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in Type 2 diabetes. Diabetes Care 2000; 23: 1130-1136
12. Rosenstock J et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901 ) and NPH insulin. Diabetes Care 2001; 24: 631-636
13. DCCT. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine 1993; 329: 977-986